Insmed Incorporated (INSM)
INSM Stock Price Chart
Explore Insmed Incorporated interactive price chart. Choose custom timeframes to analyze INSM price movements and trends.
INSM Company Profile
Discover essential business fundamentals and corporate details for Insmed Incorporated (INSM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Jun 2000
Employees
1.27k
Website
https://www.insmed.comCEO
William H. Lewis
Description
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
INSM Financial Timeline
Browse a chronological timeline of Insmed Incorporated corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.70, while revenue estimate is $392.53m.
Earnings released on 7 May 2026
EPS came in at -$0.76 surpassing the estimated -$0.96 by +21.11%, while revenue for the quarter reached $305.96m , beating expectations by +1.71%.
Earnings released on 19 Feb 2026
EPS came in at -$1.54 falling short of the estimated -$1.07 by -43.93%, while revenue for the quarter reached $263.84m , beating expectations by +14.10%.
Earnings released on 30 Oct 2025
EPS came in at -$1.75 falling short of the estimated -$1.33 by -31.58%, while revenue for the quarter reached $142.34m , beating expectations by +23.30%.
Earnings released on 7 Aug 2025
EPS came in at -$1.70 falling short of the estimated -$1.30 by -30.77%, while revenue for the quarter reached $107.42m , beating expectations by +3.16%.
Earnings released on 8 May 2025
EPS came in at -$1.42 falling short of the estimated -$1.34 by -5.97%, while revenue for the quarter reached $92.82m , beating expectations by +1.48%.
Earnings released on 20 Feb 2025
EPS came in at -$1.32 falling short of the estimated -$1.17 by -12.82%, while revenue for the quarter reached $104.44m , beating expectations by +2.31%.
Earnings released on 31 Oct 2024
EPS came in at -$1.27 falling short of the estimated -$1.20 by -5.83%, while revenue for the quarter reached $93.43m , beating expectations by +0.07%.
Earnings released on 8 Aug 2024
EPS came in at -$1.94 falling short of the estimated -$1.24 by -56.45%, while revenue for the quarter reached $90.34m , beating expectations by +2.71%.
Earnings released on 9 May 2024
EPS came in at -$1.06 surpassing the estimated -$1.24 by +14.52%, while revenue for the quarter reached $75.50m , missing expectations by -2.90%.
Earnings released on 22 Feb 2024
EPS came in at -$1.28 falling short of the estimated -$1.13 by -13.27%, while revenue for the quarter reached $83.69m , beating expectations by +1.58%.
Earnings released on 26 Oct 2023
EPS came in at -$1.10 falling short of the estimated -$1.06 by -3.77%, while revenue for the quarter reached $79.07m , missing expectations by -0.07%.
Earnings released on 3 Aug 2023
EPS came in at -$1.78 falling short of the estimated -$1.10 by -61.82%, while revenue for the quarter reached $77.23m , beating expectations by +9.98%.
Earnings released on 4 May 2023
EPS came in at -$1.17 falling short of the estimated -$1.08 by -8.33%, while revenue for the quarter reached $65.21m , beating expectations by +1.09%.
Earnings released on 23 Feb 2023
EPS came in at -$1.20 falling short of the estimated -$1.00 by -20.00%, while revenue for the quarter reached $59.30m , missing expectations by -4.49%.
Earnings released on 27 Oct 2022
EPS came in at -$1.09 falling short of the estimated -$0.89 by -22.47%, while revenue for the quarter reached $67.73m , beating expectations by +1.31%.
Earnings released on 4 Aug 2022
EPS came in at -$0.80 surpassing the estimated -$0.89 by +10.11%, while revenue for the quarter reached $65.22m , beating expectations by +10.93%.
Earnings released on 5 May 2022
EPS came in at -$0.80 surpassing the estimated -$0.91 by +12.09%, while revenue for the quarter reached $53.11m , missing expectations by -0.32%.
Earnings released on 17 Feb 2022
EPS came in at -$0.95 falling short of the estimated -$0.89 by -6.74%, while revenue for the quarter reached $56.12m , beating expectations by +11.47%.
Earnings released on 28 Oct 2021
EPS came in at -$0.96 falling short of the estimated -$0.83 by -15.66%, while revenue for the quarter reached $46.76m , missing expectations by -6.88%.
Earnings released on 5 Aug 2021
EPS came in at -$0.94 falling short of the estimated -$0.85 by -10.59%, while revenue for the quarter reached $45.37m , beating expectations by +3.76%.
INSM Stock Performance
Access detailed INSM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
